EU regulators back Novartis inhaler, Gilead HIV drug

LONDON (Reuters) – European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences. Recommendations for marketing approval by the agency’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. (Reporting by Ben Hirschler; editing by Kate Kelland)
Sexual Health News Headlines – Yahoo! News